 The combination of Bevacizumab and Erlotinib show encouraging activity for patients with previously treated, non-small-cell lung cancer. In a phase III study of erlotinib and bevacizumab in patients with nonsquamous stage IIIBIV NSCLC with one or more prior chemotherapy exposures, a recommended phase II dose was established at erlotinib 150 mgday orally plus bevacizumab 15 mgkg intravenously every 21 days 13 Forty patients were treated at the recommended Phase II dose. The median age was 59 years range, 36 to 72 years, 21 were female, 30 had adenocarcinoma histology, nine were never-smokers, and 22 had or two prior regimens three patients had or four prior regimens. The most common adverse events were mild to moderate rash, diarrhea, and proteinuria. No pharmacokinetic interactions were identified. Eight patients 20.0; 95 CI, 7.6 to 32.4 had partial responses and 26 65.0; 95 CI, 50.2 to 79.8 had stable disease as their best response. The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months. These data compare favorably with conventional chemotherapy in the salvage setting for NCSLC where the response rates are 10 and median survivals are 6-8 months 14-16. 